Good morning, everyone, and welcome to the JP Morgan Healthcare Conference. It is my pleasure to introduce you today to the Blueprint Medicines team. We have Kate Haviland, who is the CEO, who will be leading the presentation today, Christy Rossi, who is COO, and Fouad Namouni, who is President R&D, will be joining Kate during the Q&A. Post the presentation, we will set up some time for Q&A. With that, I will hand it over to Kate. Kate, thank you so much for joining us here today, and we look forward to the presentation. Thank you very much, Malika. So, good morning, everyone, and thank you very much to Phil Ross and the entire JP Morgan team for inviting us here to present this year. I want to welcome everyone in the room. It's nice to see so many people here in person and all of those who are joining us online through the webcast. As Malika said, my name is Kate Haviland. I actually joined Blueprint Medicines eight years ago in 2016, and just stepped into the President and CEO role two years ago. I'm very happy to be joined here by both Christy Rossi, our Chief Operating Officer, and Fouad Namouni, our President of R&D. So, in the end, I am representing the work of all of my Blueprint colleagues. We had a tremendous 2023 as we made our mission at Blueprint into our reality. What that means for me is that our strong execution in 2023 has allowed us to realize the harmony between our mission of bringing new innovative medicines to patients and building a thriving and strong business, both of which I'll talk about today. During the presentation, I will make some forward-looking statements. I refer you to our recent SEC filings for updated risk factors. What we have achieved in the last 13 years at Blueprint Medicines is remarkable. We have built a fully integrated global infrastructure and a strong foundation of expertise and capabilities. During our first 10 years, we imagined and built a new drug discovery platform that consistently has churned out innovative molecules against important biological targets, and we proved that we can make medicines that work. In the more recent years, we have now successfully brought forward AYVAKIT, a fundamental new treatment for systemic mastocytosis, or SM, across the spectrum of the disease. We've established a durable leadership position in SM. Now, looking forward, AYVAKIT has the potential to be a blockbuster medicine that can drive long-term growth, forming the foundation of our thriving business and enabling us to invest in additional compelling growth opportunities to deliver even more transformative medicines to patients in the future. I am very proud of the significant progress we made across all aspects of our business in 2023. We achieved all of our goals while maintaining financial discipline. The first and most important was our approval and launch of AYVAKIT in ISM. We also made tremendous progress across both our development and discovery portfolios, and we did all of this very efficiently, decreasing our year-over-year operating expenses. This tremendous execution that our entire team was able to achieve puts us in a tremendous position in 2024 with great momentum. Our key imperatives to drive growth this year are the continued revenue acceleration and top-line growth driven by AYVAKIT. As we continue the launch in the U.S., and we start to bring AYVAKIT to patients ex-U.S. with our E.U. approval that happened at the end in December of 2023. We have just started to scratch the surface on treating patients with SM who could potentially benefit with AYVAKIT. This year, we'll continue to reach more of those patients, and we're looking forward to updating you on how we think about that opportunity at our Q4 call in a few weeks. We are also investing in prioritized programs in focused areas such as mast cell-driven disorders, where there is high medical need in large patient populations, and importantly, where we can also leverage our expertise and our infrastructure. This disciplined capital allocation, combined with accelerating top-line revenue growth, enables us to maintain a strong and durable financial position and to reach a self-sustaining financial profile, while at the same time investing in a range of programs that can drive both near and long-term growth of the company. So I'm going to start now looking a little bit more at our top-line revenue growth driver with AYVAKIT. Oops, sorry. Our ongoing launch in ISM is one of the most exciting rare disease launches happening in our industry today. I say that because of AYVAKIT's unique value proposition and multidimensional opportunity for driving growth. Let's start with AYVAKIT's blockbuster potential. We know that the first few quarters of launch are critical in defining the trajectory of growth for a new product. In our first full quarter of launch, we delivered results both in our ability to reach patients and to drive revenue. We grew revenue from Q2 to Q3 by 36%, and we expect continued, strong, and steady revenue growth throughout 2024. On the right of this slide, what you see are the key attributes of the AYVAKIT's opportunity in SM that really form the basis of our conviction in the blockbuster potential. First, ISM represents a significant rare disease opportunity.... It is about 15 times larger of a patient population than what, than advanced SM. That actually equates to about or a little bit greater than 70,000 patients who are diagnosed with SM in the U.S. and Europe. Tremendous opportunities for growth as we continue to penetrate that population. Also, as we're increasing the number of ISM patients on therapy this year, we expect to see the cumulative effects of patients staying on therapy become a more significant driver of revenue in 2024 and beyond. ISM is a burdensome, lifelong disease in which chronic treatment is necessary to maintain patients with durable symptom control. Another key point is that SM is a specialty market with a very tractable set of prescribers in hematology, oncology, and allergy immunology, which allows us to reach these prescribers with efficient and focused infrastructure. And lastly, another very important point is that we have long IP protection on AYVAKIT that will allow us to drive growth well into the next decade. Now, as a reminder, AYVAKIT is the first and only therapy approved in ISM, and its clinical profile is impressive, setting a very high bar for any future therapies to come. So let's take a little bit more of a look at AYVAKIT's clinical profile. The pivotal PIONEER study demonstrated that treatment with AYVAKIT resulted in significant improvement across a wide range of symptoms for patients with ISM. This impressive efficacy was complemented with a very well-tolerated safety profile, where patients do not have to trade off symptom control with side effects that mimic aspects of their disease. With the ongoing PIONEER study, we now have patients who've been treated out to four years and have stayed on therapy. We'll be presenting both that long-term safety experience as well as the durability of symptom control at medical meetings this year. We also designed a flexible dosing regimen. In a disease like SM that is comprised of a heterogeneous spectrum of patients in terms of the symptoms they experience as well as the severity of their disease, we know that a one-size-fits-all approach to treatment doesn't work. To ensure there's an AYVAKIT solution for all potential patients, from those with more aggressive disease, such as those with mast cell leukemia, to those with more attenuated disease, we have made four AYVAKIT doses commercially available. This enables physicians to optimize treatment for the individual needs of the patient who's sitting in front of them. We've heard regularly from the physician community that this is incredibly important to them in terms of being able to flexibly address patient needs. Now, let's talk about how this PIONEER data in the study that we saw is now translating and playing out in the real world. As I mentioned, the first few quarters of a launch are critical to building the foundation of growth. I'm going to walk through on this slide a few of the metrics that really underscore the strength of this initial launch that we've had in ISM. We know that we needed to broaden our prescribing base as we launched in ISM, especially as we started to interact with a new set of physicians in the allergy immunology space. And we have done just that, with 60% of our Q3 volume coming from new prescribers, with significant headroom to grow as we continue to get new prescribers coming in from allergy immunology. We've done this while also deepening prescribing, and 40% of Q3 demand has come from repeat AYVAKIT prescribers, either those who are early adopters in the ISM space or have had previous AYVAKIT experience. Really a testament to how strong the AYVAKIT profile is and that people have strong experiences with the drug when they treat their first patients. We also knew that adoption needed to happen broadly, not just in the academic setting, but also in the community setting, so that we can meet patients where they are. And indeed, that is exactly what we've seen, with 50% of the volume coming from academic setting, treatment settings, and 50% community. We are very pleased to see this early in the launch, such a strong split between these two treatment settings. In rare disease launches, awareness is a key success factor to drive demand. Our medical and commercial teams have been very effective at empowering healthcare providers and patients with information through publications, presentations, in-person presence at national meetings, as well as at regional meetings, and in broad digital communications. We've seen the fruits of those efforts really paying off in terms of awareness. And lastly, we know that broad and unencumbered access is critical. Our market access team has delivered right out of the gate, achieving industry-leading metrics on converting physician prescriptions to patients on therapy very early in launch. These metrics are impressive, particularly for an innovative new medicine that is building a new therapeutic category. They give us the—they give me and our entire team the confidence in our trajectory of growth, and that we will continue to drive this year. We are just getting started. We are at the very early stages of this launch, and we see significant upside across multiple dimensions, starting with continuing to drive uptake in patients who have moderate to severe ISM. With increased awareness and diagnosis, we now estimate the number of diagnosed ISM patients who are not well controlled on symptomatic-directed therapy at 9,500 patients in the U.S., based on our claims analysis. At the end of Q3, we were treating approximately 800 patients in the U.S., meaning there is significant headroom to grow adoption in this group of patients in 2024. We are also very pleased to have received a broad label from the FDA, which gives latitude to physicians and patients in considering who could benefit from AYVAKIT treatment. We've already seen patients coming on to initiating commercial therapy, who would not have been eligible to participate in our PIONEER clinical study. We are continuing to build the market with more efficient diagnosis, and in the last year alone, we've seen a 20% growth in the number of diagnosed patients in with SM, now around 21,000 patients in the U.S. All of these numbers you see on this slide are U.S.-only numbers. As we expand outside the U.S., we have another dimension of growth that is really coming into focus this year. As I mentioned, we got AYVAKIT approved in the EU in December, and it was able to actually already start commercial patients on therapy in Germany before the end of the year. Okay, shifting gears, I now want to focus a little bit more in on our R&D portfolio. A core component of our growth strategy is to build around our leadership position in SM by expanding to other mast cell diseases, mast cell-driven diseases. At the top of this slide, you'll see that we are building portfolio scale in the area of allergy and inflammation. And in a few moments, I'm going to spend a couple of minutes talking about the most progressed and late-stage programs in that portfolio, being elenestinib and BLU-808, our wild-type KIT inhibitor. This part of our portfolio is where we have fully integrated infrastructure from discovery through commercial, and we tend to bring these programs forward ourselves. At the bottom of this slide, you see our programs that make up our solid tumor portfolio. This is anchored by BLU-222, one of the most exciting programs that we have in clinical development. Given the enormous potential of BLU-222, we are welcoming the opportunity to collaborate with a partner who has a shared view of the importance of CDK2, CDK2 as a target in breast cancer and other solid tumors, as well as the compelling profile of BLU-222 as a potential best and first-in-class CDK2 inhibitor. We have had significant engagement on this program from a range of potential partners, and those conversations continue very productively. We also have a number of other undisclosed programs. It's just one line, but there's a lot in there. And these are programs our team in discovery is working on, very exciting biological targets that we're going to be looking forward to talking to you about in future years. I am particularly pleased with how quickly our new platform in targeting protein degradation has become established and is now really driving programs into the clinic, which you see some even represented here in this pipeline. What you do not see on this slide are the programs we have targeting EGFR-driven non-small cell lung cancer. In fact, last year at this meeting, I highlighted that one of our goals for 2023 was to generate data across a number of our phase I programs to enable us to make data-driven decisions and investments in the most promising programs that we see to move forward and to start answering two really important questions. One, is, are our molecules indeed best in class? And two, can we replace the standard of care in frontline EGFR-driven lung cancer? Our development team has done a tremendous job over the course of last year, executing against these early phase I programs and provided us the data we need to make prioritization decisions across our portfolio. Combining this emerging data from both the BLU-945 and the BLU-451 programs with the evolving EGFR landscape, we have decided to deprioritize continued investment in EGFR-driven non-small cell lung cancer and to focus our R&D investments in the most compelling and highest value programs that you see here on this slide. We are extremely excited about the potential of these programs that we are moving forward to impact patients and to drive growth of the company. So let's now turn to how we plan to lead in the mast cell disorder space. So we at Blueprint are uniquely positioned to build a franchise in mast cell-mediated diseases because of our scientific leadership in KIT, that has started from the founding of the company, and our now proprietary insights we have developed around mast cell disease biology. We know, as you see in the left-hand side of this slide, that KIT plays a central role in mast cell survival, proliferation, and activation. KIT-mediated signaling leads to mast cell degranulation, which is the release of multiple inflammatory molecules that lead to this range of debilitating and burdensome symptoms for patients. On the right part of the slide, what you see is that beyond our scientific expertise, we also have a unique edge based on our SM experience, in which we've already demonstrated our ability to design molecules that can target the core biology of these diseases and that have a therapeutic index and tolerability profile that is conducive for chronic treatment. We know how to execute complex clinical programs that bridge translational biology insights into data packages that can result in global regulatory approvals. We have established relationships with a broad range of global KOLs in the allergy immunology space, as well as a seat at the table with healthcare providers who take care of these patients day in and day out across the United States and now also in Europe. I have personally had an opportunity to hear from many of these healthcare providers about the profound need they see for new treatments for many of their patients who have allergic inflammatory diseases driven by mast cells. With AYVAKIT and elenestinib, we are fully covering diseases that are driven by mutated KIT, and we are now expanding into the much larger disease opportunities that are driven by wild-type KIT, including chronic urticaria, as well as Type 2 asthma, idiopathic mast cell activation syndrome, and a range of other respiratory GI and skin disorders. So let's dig a little bit into our two most advanced programs here, elenestinib and BLU-808. Starting with elenestinib, the data we just recently presented at ASH demonstrate that you'll see here on the right demonstrate that elenestinib drives clinically meaningful symptom improvements across dose levels with a very well-tolerated safety profile, including no patients that had discontinued therapy due to adverse events. I know everyone is eager to understand how do we plan to bring elenestinib forward into the registration-directed part of the HARBOR Part 2 study. We will share more of those plans in the second half of this year. But as I said earlier in the presentation, AYVAKIT's impressive efficacy and safety make it extremely hard to beat. So we are not going to just replicate the AYVAKIT development path. We are going to actually forge new ground based on the important insights that we have developed through the context of the PIONEER study. We're going to continue to work collaboratively with the global SM community to develop elenestinib for where, using a very overused analogy, but for where the puck is going in SM, not where we are today. We'll have a lot more to say on this later in 2024, and we look forward to updating you all at that point. Now, moving to BLU-808, our wild-type KIT inhibitor. Today, for the first time, we are sharing you a bit more detail on BLU-808's profile. So when we set out to bring forward a wild-type KIT inhibitor, we defined an ideal target product profile, which you see at the middle of the slide in the table. BLU-808 not only meets but exceeds the criteria we laid out. It is potent on KIT, it is highly selective, and it has drug-like properties compatible with once-daily oral administration. We are on track to submit our IND for BLU-808 in the second quarter of this year. At the bottom of the slide, we're actually including a video that you can access if you scan the QR code. The video shows how inhibiting wild-type KIT is a very robust strategy to stop mast cell degranulation. We are very excited about this program. I know a lot of you are as well. We are also hearing firsthand from numerous physicians who treat ISM, and they also treat chronic urticaria, about their excitement for an oral wild-type KIT inhibitor, specifically because of the potential of this game-changing approach to change the treatment of CU. Chronic urticaria will be the first patient population we begin development of BLU-808 in. Chronic urticaria is a terrible and debilitating inflammatory skin disorder characterized by wheals or hives, and you can see that here in the picture on the left-hand side of the slide. There is strong clinical proof of concept that targeting KIT impacts the core biology of this disease and is potentially the most promising way to improve patient symptoms and outcomes. There are also a large number of patients with CU who continue to have significant medical need despite current available therapeutic options. We think we can raise the bar on what a new treatment can offer, taking into account the full patient experience, efficacy, safety, and route of administration. There's a clear opportunity for an oral KIT-targeted treatment to expand the treatment population in CU. Transitioning now from our plans to build scale in mast cell-driven diseases, let's now turn to solid tumors with a focus on BLU-222. Our BLU-222 program is an important driver of value for Blueprint, which we are looking to move forward, as I said before, in the context of a partnership. So why do we have such strong conviction in BLU-222's potential? The first is the strength of the underlying science on the role of CDK2 in cancer. CDK2 is a clinically validated cell cycle target, and I'd say at ASCO in 2023, what we saw was clinical validation of CDK2's importance with unexpected single-agent activity from two different programs: our program at BLU-222 and in Pfizer's program. The second reason is the potential to impact large patient populations. The opportunity in HR+ metastatic breast cancer is a large market, and there are significant medical needs, where nearly all patients progress even on the improved therapies that we have today. There's also strong evidence that CDK2 activation is a key mechanism of resistance to current CDK4/6 targeted medicines, and the market in 2023 for those medicines was, is greater than $10 billion. So our goal is to combine our CDK2 inhibitor with existing and approved CDK4/6 targeting medicines to provide patients with deeper and more durable responses. Sounds simple. However, true CDK2 selectivity has historically been extremely difficult to achieve. And the lack of selectivity versus other CDK family members has led to multiple programs being discontinued. And this is where Blueprint's unique expertise comes to bear. We have solved the chemistry challenge of selective CDK2 inhibition with BLU-222. So let's look more closely at BLU-222's profile, which you can see here, I summarized on this slide. So at the top of the chart, you see that BLU-222 has excellent overall kinome selectivity and importantly, high CDK2 potency with selectivity over other CDK family member targets. So the question is: How is this profile now translating into the clinic? And on this slide, we're also showing some of the safety data from the VELA study, monotherapy dose escalation of BLU-222. Now, I want to make sure it's clear that this is actually slightly different data than what we showed at ASCO. Here we are focusing on treatment-emergent adverse events in order to make a more apples-to-apples comparison. I also want to point out that this is a cross-trial comparison, and both of these studies are phase II dose escalation studies, where patients are treated at multiple dose levels with multiple tumor types. Having said that, what we see here is a very encouraging profile for BLU-222. It has a broad therapeutic window, it has favorable pharmacokinetic properties, including half-life and PK. And most importantly on this slide is the side effect profile, which we believe will make BLU-222 the combination partner of choice. Specifically focusing here on the hematologic adverse events, which is an area where we do not want to see significant overlapping toxicities with approved CDK4/6 medicines, and where BLU-222 has demonstrated a very favorable profile. We are continuing dose escalation of BLU-222 in combination with ribociclib and fulvestrant, and we look forward to presenting more of that data this year. Our development strategy, based on this profile, is to combine with already approved CDK4/6 targeted medicines, which we believe will allow BLU-222 to move more quickly through the clinic and to potentially be the first-in-class CDK2 inhibitor approved. Let's now turn to the strength of our financial profile. As I already touched upon, I am extremely pleased with our early launch trajectory, and we are looking forward to that strong and steady revenue growth throughout 2024. We plan to announce Q4 and full year results on our Q4 earnings call in a few weeks, and at that time, we'll also provide guidance that includes the ISM opportunity, so across the entire AYVAKIT brand. However, stepping back, the real value of this brand is what we can achieve over the long term. As we grow throughout 2024, we will still just be scratching the surface of this opportunity with thousands of more patients who could potentially benefit with treatment over time, which really gives us that conviction that this is greater than a 1.5 global blockbuster opportunity. Importantly, this top-line revenue growth also gives us a line of sight to profitability. As our revenues ramp, cash management will continue to be a priority area of focus for us. We are taking a very disciplined approach to operating expenses. Over the last six quarters, OpEx has been flat or declining, and we expect OpEx to decline year-over-year as we have prioritized and focused investments in the programs where we have the most conviction. On the right-hand side of the slide, what you see is an illustration that focuses on cash burn. Our continued top-line growth and decline in operating expenses will also mean that our net cash burn will decline. We expect this decline in cash burn to be even more significant in 2024 than it has been in 2023. And as you extrapolate that dynamic, we are confident that our durable capital position will enable us to remain independent of capital markets for the foreseeable future. Here, we're highlighting the priorities and key catalysts for the company over the course of the year. 2024 is going to be a very important year for us at Blueprint. I look forward to updating you all on our progress against these milestones as we progress. So in conclusion, we are kicking off 2024 from a position of strength as we realize the harmony between our our mission of bringing new therapies to patients and building a strong and thriving financial business. We are delivering on our commitment to rapidly bring AYVAKIT, a first-in-class medicine, to all SM patients who could benefit. Our launch in ISM represents one of the most exciting rare disease launches happening today. With strong and steady growth that we've experienced to date, we are on track to capture that tremendous long-term growth opportunity that that AYVAKIT has in SM. Second, we are focusing investment and resource allocation to exciting development programs with opportunities to address high medical need in large populations, in areas that play to our strengths, where we have expertise, where we have infrastructure, where we have a track record of success. As we sit here today, we have a clear path to profitability through a combination of strong revenue ramp and disciplined operating expenses, resulting in a significant cash burn in 2024 and beyond. Together, these three factors taken will enable us to drive near-term and long-term growth while enhancing long-term shareholder value at the same time.... So in addition to the corporate strategy that I just laid out today, it is really our people who drives the success at Blueprint Medicines. And I want to thank all of my Blueprint Medicines colleagues for their hard work, their contributions in driving these results, and their dedication to our mission. So with that, I think we're going to turn to Q&A. Maybe I'll leave it here. Okay, thank you for sharing the presentation, and congratulations to the Blueprint team for all that you have achieved this past year. Thank you so much. We will now open up to audience Q&A. We have a runner with a mic, so if you raise your hand, we can hand over the mic for the question. Kate, maybe to kick off, we can start with some big picture strategy. You announced a very clear pipeline prioritization. Yes. Where are you leaning in, and where are you leaving out? Thank you for that question. I mean, we are really focused on continuing to build scale and invest in the programs where we think we have the most opportunity to make a difference for patients, and that is in allergy, inflammation, and mast cell-driven disorders, and then also in some of those solid tumor programs that I mentioned. We do feel that we have incredible strength, particularly, based on our SM experience and the global infrastructure we have built to bring AYVAKIT and SM to patients globally, that we can continue to leverage that infrastructure and that expertise to build more scale around mast cell-driven diseases. We also really like the science and unmet need there. Fouad, I don't know if you want to lean in on that or talk about that a bit. I think the way we think about Blueprint is, you know, in terms of portfolio, we lead the research and development of ISM, which is the tip of the iceberg of mast cell disorders. Our expertise over the last many years, understanding the biology of mast cells and working with AYVAKIT, with elenestinib, and now with BLU-808, really is allowing us to go beyond this tip of the iceberg to the broader population of patients where mast cell is the root cause of the disease. So we're precisely tackling the root cause of the disease. Our belief in KIT biology beyond ISM and beyond the mutation of KIT is showing up in a variety of data we are seeing, and very important to make a difference in patients' lives beyond ISM. Thank you. Maybe a quick follow-up would be: How does this approach impact the durability of your cash position moving forward? Yeah, absolutely. I mean, I think this, this area, this focus, actually very much enables us to maintain that durable cash position. And so, you know, we had a number of programs that we are prosecuting through development in 2023, and we were able to get to those early phase I datasets or beyond, for some programs like elenestinib and others, to allow us to make very strategic investment decisions on the opportunities we think are most compelling in terms of their ability to help patients and drive growth of the company. And so where we are focusing our investment now is on mast cell-driven disorders, as Fouad just mentioned, as well as in some of these, kind of very exciting areas of solid tumor biology, like our CDK2 program, BLU-222. And we've really narrowed that focus and we're excited to bring those programs forward and just show the progress against those this year. Yeah. Yeah. A question- Do you want me to? No, you can go ahead. First question. On BLU-808, you said that's going to go into the clinic midyear. Do you think we'll see data this year, or is that more of a next year event? Maybe, maybe I'll repeat for those on the webcast. So the question was around BLU-808, and that we are, we are on track to file the I&D by second quarter of this year. So the question is: When will we see data from BLU-808? I think we'll see some preclinical data from 808. As you, Kate mentioned that you appreciate the first time we start disclosing the profile of 808, which we think is not only going to be the best, but certainly the first in class in targeting wild-type KIT. In Q2, we will file the IND, and right away, we will start the healthy volunteer study. So, I would expect more preclinical data in the coming months. And then a second question: On the $1.5 billion in sales, what's the breakdown between advanced SM and ISM? Christy, you want to take that? Sure. Yeah, so, as you said, we see SM as a north of $1.5 billion opportunity. The vast majority of that value lies in ISM. Certainly, the approval in ISM in the U.S. has driven a really compelling inflection in revenue, which we saw in Q3, and we are just beginning to penetrate that patient opportunity. It's 90%-95% of the patients are indolent patients. Indolent patients also are chronically treated patients, and I think a really important value driver of this commercial opportunity is keeping these patients on treatment for extended durations, years. And so certainly, we see... While we continue to see growth in advanced SM as well, the indolent opportunity is really the catalyst that we are capitalizing on to drive growth for AYVAKIT going forward. Maybe another question is- Sure. Is there anything you can share with us about GAVRETO? Sure. Do you want to? Sure. So, as everyone I think is aware, last year, we announced that Roche had made a decision to terminate the global collaboration for GAVRETO. Today, we did provide an update on that, and indicated that outside the US, we will be winding down GAVRETO development as well as commercialization globally. Blueprint, unfortunately, does not have infrastructure in lung and thyroid, and as we talked about today, our focus is very much on driving AYVAKIT forward in SM. In the United States, we do have a potential party who is interested, and we're continuing to have discussions amongst the parties to find a way forward to keep GAVRETO available to patients in the United States. So, more to come there. I think the most important thing from a, you know, a Blueprint corporate perspective is that our investment in GAVRETO significantly declines in 2024, and regardless of how this situation is resolved, we don't expect GAVRETO to materially impact our financial situation as we go forward. Thank you. And since we have only a couple of minutes left, maybe one last question: How is Blueprint of 2024 gonna be different from Blueprint of the prior years? Gosh, I feel like we're in one of the most exciting positions we've ever been in. I think you see the evolution of the company is very much defined by the tremendous success we've had to date in systemic mastocytosis and how we're gonna look to build on that success as we leverage our scientific expertise, our development capabilities, and now our commercial relationships and infrastructure globally. So it's really an exciting time as we think about focusing on the tremendous opportunity that exists in mast cell-driven disorders, bringing some of that kind of translational expertise that is so strong in oncology to this therapeutic area, which we're very excited about. So... Thank you. With that, we will be closing out the session. Thank you, Kate, Christy, and Fouad, for the very informative session, and thank you all for joining us here today.